RPRX
Royalty Pharma
$58.75
−$1.84 (−3.04%)Sep 10, 2026
Key metrics
The numbers that frame RPRX today
- Market cap
- $33.78B
- P/E (TTM)
- 41.4
- EV / FCF
- 14.3
- Gross margin
- 100%
- EV / Sales
- 16.5
- ROIC
- 4.5%
- Div yield
- 1.55%
- Debt / equity
- 0.9
- 52wk Low
- $33.97
- 52wk High
- $64.38
Growth
Revenue and earnings trend for RPRX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RPRX
Is Royalty Pharma a good buy?
Yes. Royalty Pharma has mixed quality and excellent momentum. Taken together, the setup leans positive. Growth looks mixed. The support signal is useful, but not decisive. We think Royalty Pharma is selling at a fair price.
What is the market capitalization of RPRX?
Royalty Pharma's market capitalization is $33.78B.
What is the P/E ratio for RPRX stock?
Royalty Pharma's current P/E ratio is 41.4.
What is the 52-week high for RPRX stock?
The 52-week high for Royalty Pharma is $64.38. The current close of $58.75 is 8.7% below that high.
What is the 52-week low for RPRX stock?
The 52-week low for Royalty Pharma is $33.97. The current close of $58.75 is 72.9% above that low.
Does RPRX stock pay dividends?
Royalty Pharma pays a dividend. The latest dividend per share in the company data is $0.91, which implies a yield of 1.55% based on the current close.
What is the Debt / Equity ratio for RPRX?
Royalty Pharma's Debt / Equity ratio is 0.92.